Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients

被引：28

作者：

Barg, Assaf A. ^{[1
,2
]}

Malkiel, Sarah ^{[1
,2
]}

Bartuv, Maya ^{[3
]}

Greenberg, Gahl ^{[4
]}

Toren, Amos ^{[1
,2
]}

Keller, Nathan ^{[5
,6
]}

机构：

[1] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Dept Pediat Hematol Oncol & BMT, Ramat Gan, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Sheba Med Ctr, Pharm Serv, Ramat Gan, Israel

[4] Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel

[5] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Infect Dis Unit, Ramat Gan, Israel

[6] Ariel Univ, Dept Hlth Management, Ariel, Israel

来源：

PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 10期

关键词：

immunocompromised; isavuconazole; mucormycosis; pediatric; MOLD INFECTIONS; RISK-FACTORS; CHILDREN; GUIDELINES; DISEASE;

D O I：

10.1002/pbc.27281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundInvasive mold infections (IMIs) are a leading cause of mortality among immunocompromised patients. Isavuconazole is a new drug that shows promise in the adult population for the treatment of IMIs. No data regarding the use of isavuconazole in pediatric patients have been published. MethodsPatients with a diagnosis of IMI from our pediatric hemato-oncology division, treated with isavuconazole between 2010 and 2016, were identified using the hospital's computerized database. Data including demographics, clinical course, and outcome were collected. Pharmacokinetic samples were obtained from two younger patients to guide dosing. ResultsIn total, three patients (4.5, 5, and 19 years of age) with invasive mucormycosis who were treated with isavuconazole were identified. All patients were treated with isavuconazole as a second line therapy and experienced improvement following the initiation of this treatment. ConclusionsBased on our limited clinical experience, isavuconazole may be a safe and effective treatment option for children and adolescents afflicted by IMI. Prospective clinical trials should be performed in order to evaluate the pharmakokinetics and safety of isavuconazole in the pediatric population.

引用

页数：5

共 24 条

[1] Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review [J].

Al-Rezqi, Abdulkader ;

Hawkes, Michael ;

Doyle, John ;

Richardson, Susan E. ;

Allen, Upton .

PEDIATRIC TRANSPLANTATION, 2009, 13 (05) :545-552

[2] Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications [J].

Autmizguine, Julie ;

Guptill, Jeffrey T. ;

Cohen-Wolkowiez, Michael ;

Benjamin, Daniel K., Jr. ;

Capparelli, Edmund V. .

DRUGS, 2014, 74 (08) :891-909

[3]

Chesney RW, 2004, PEDIATRICS, V113, P1128

[4] ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013 [J].

Cornely, O. A. ;

Arikan-Akdagli, S. ;

Dannaoui, E. ;

Groll, A. H. ;

Lagrou, K. ;

Chakrabarti, A. ;

Lanternier, F. ;

Pagano, L. ;

Skiada, A. ;

Akova, M. ;

Arendrup, M. C. ;

Boekhout, T. ;

Chowdhary, A. ;

Cuenca-Estrella, M. ;

Freiberger, T. ;

Guinea, J. ;

Guarro, J. ;

de Hoog, S. ;

Hope, W. ;

Johnson, E. ;

Kathuria, S. ;

Lackner, M. ;

Lass-Floerl, C. ;

Lortholary, O. ;

Meis, J. F. ;

Meletiadis, J. ;

Munoz, P. ;

Richardson, M. ;

Roilides, E. ;

Tortorano, A. M. ;

Ullmann, A. J. ;

van Diepeningen, A. ;

Verweij, P. ;

Petrikkos, G. .

CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 :5-26

[5] Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases [J].

Daebritz, Jan ;

Attarbaschi, Andishe ;

Tintelnot, Kathrin ;

Kollmar, Nina ;

Kremens, Bernhard ;

Loewenich, Friederike D. v. ;

Schrod, Lothar ;

Schuster, Friedhelm ;

Wintergerst, Uwe ;

Weig, Michael ;

Lehrnbecher, Thomas ;

Groll, Andreas H. .

MYCOSES, 2011, 54 (06) :E785-E788

[6] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

[7] Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: a case report and review of the literature [J].

di Coste, Annalisa ;

Costantino, Francesco ;

Tarani, Luigi ;

Savastano, Vincenzo ;

Di Biasi, Claudio ;

Schiavi, Laura ;

Ernesti, Ilaria ;

Melengu, Taulant ;

Duse, Marzia .

ITALIAN JOURNAL OF PEDIATRICS, 2013, 39

[8] Risk Factors of Amphotericin B Toxicity in the Nonneonatal Pediatric Population [J].

Dutta, Ankhi ;

Palazzi, Debra L. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (09) :910-914

[9] Successful isavuconazole salvage therapy in a patient with invasive mucormycosis [J].

Ervens, J. ;

Ghannoum, M. ;

Graf, B. ;

Schwartz, S. .

INFECTION, 2014, 42 (02) :429-432

[10]

Falci Diego R, 2013, Infect Drug Resist, V6, P163, DOI 10.2147/IDR.S51340

← 1 2 3 →